- Espace patient.e.s
- Vie du GTE
Prospective Study Evaluating the Medullary Thyroid Cancer Management’s Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin (CMTpostopFDOPA)
Toulouse, Institut Claudius Regaud
Bordeaux, Limoges, Marseille, Montpellier, Toulouse
The purpose of the study is to evaluate the impact and performance of a new PET / CT (computerized tomography ) tracer targeting dopamine receptor in patient with residual ganglionar biological disease after initial surgery of medullary thyroid cancer compared to standard imaging.
Relative rate of TRUE positive nodes with PET F-DOPA compared to standard imaging assessment. [ Time Frame: up to 3 years ]
• Age > or = 18 years.
• Patient with medullary thyroid cancer (sporadic or hereditary form).
• Patient treated by total thyroidectomy with uni or bi-lateral lymph node dissection (in the central and/or lateral neck compartment).
• Patient with elevated thyrocalcitonin rate > or = 150 pg/ml assessed within 6 weeks or more after surgery.
• Patient with standard imaging assessment performed during 3 months before PET 18-FDOPA.
• Standard imaging assessment including at least a cervical ultra-sound, a cervico-thoracic CT-scan and/or a cervico-thoraco-abdomino-pelvic CT-scan and a liver MRI.
• Patient able to be followed at least 6 months after PET 18-FDOPA.
• If women are breastfeeding, nursing should be discontinued during 24 hours after PET 18-FDOPA.
• Patient must provide written informed consent prior to any specific procedure or assessment.
• Patient must be affiliated to the French Social Security System.
• Pregnant patient.
• Post-operative radiotherapy initiated before PET 18-FDOPA.
• Patient with PET 18-FDG performed within 24 hours before PET 18-FDOPA.
• Participation in any other clinical trial for therapeutic use.
• Patient with PET / CT-scan exam contra-indication.
• Any serious and/or unstable pre-existing psychological, familial, geographic or social condition that could interfere with medical follow-up and compliance to study procedures.
• Patient protected by law.